Kate 3
NCT04740918
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
Status:
Opening soon
III
Phase
1st+
Line of Therapy
Advanced / Metastatic
Disease Stage
Biomarker(s)
HER2+, PD-L1
Investigational
Product
Atezolizumab
Treatment Arms
o Trastuzumab Emtansine and Placebo
o Trastuzumab Emtansine and Atezolizumab